


FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER DEX-0113
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/700770
INTERNATIONAL APPLICATION NO. PCT/US99/10344	INTERNATIONAL FILING DATE 12 MAY 1999	PRIORITY DATE CLAIMED 21 MAY 1998		
TITLE OF INVENTION A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING LUNG CANCER				
APPLICANT(S) FOR DO/EO/US YANG, Fei et al.				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 				
Items 13 to 20 below concern document(s) or information included:				
<ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Certificate of Mailing by Express Mail <input checked="" type="checkbox"/> Other items or information: 				
Executed Verified Statement Claiming Small Entity Status <div style="border: 1px solid black; padding: 10px; margin-top: 10px;"> <p>"Express Mail" Label No. #EL777534822US Date of Deposit - November 20, 2000</p> <p>I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Box PCT, Washington, D.C. 20231</p> <p>By <i>Suzanne Sparkman</i> Typed Name: Suzanne Sparkman</p> </div>				

U.S. APPLICATION NO. (IF KNOWN SEE 37 CFR 09/700770	INTERNATIONAL APPLICATION NO. PCT/US99/10344	ATTORNEY'S DOCKET NUMBER DEX-0113																				
21. The following fees are submitted:		CALCULATIONS PTO USE ONLY																				
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :																						
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00																						
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$690.00																				
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).		<input type="checkbox"/> 20 <input type="checkbox"/> 30 \$0.00																				
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">CLAIMS</th> <th style="width: 25%;">NUMBER FILED</th> <th style="width: 25%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>11 - 20 =</td> <td>0</td> <td>x \$18.00 \$0.00</td> </tr> <tr> <td>Independent claims</td> <td>5 - 3 =</td> <td>2</td> <td>x \$80.00 \$160.00</td> </tr> <tr> <td colspan="3">Multiple Dependent Claims (check if applicable).</td> <td style="text-align: center;"><input checked="" type="checkbox"/> \$270.00</td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS</td> <td style="text-align: center;">\$1,120.00</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	11 - 20 =	0	x \$18.00 \$0.00	Independent claims	5 - 3 =	2	x \$80.00 \$160.00	Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/> \$270.00	TOTAL OF ABOVE CALCULATIONS			\$1,120.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																			
Total claims	11 - 20 =	0	x \$18.00 \$0.00																			
Independent claims	5 - 3 =	2	x \$80.00 \$160.00																			
Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/> \$270.00																			
TOTAL OF ABOVE CALCULATIONS			\$1,120.00																			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).		<input checked="" type="checkbox"/> \$560.00																				
SUBTOTAL		\$560.00																				
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).		<input type="checkbox"/> 20 <input type="checkbox"/> 30 + \$0.00																				
TOTAL NATIONAL FEE		\$560.00																				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).		<input type="checkbox"/> \$0.00																				
TOTAL FEES ENCLOSED		\$560.00																				
		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: left;">Amount to be: refunded</td> <td style="width: 50%; text-align: right;">\$</td> </tr> <tr> <td style="text-align: left;">charged</td> <td style="text-align: right;">\$</td> </tr> </table>	Amount to be: refunded	\$	charged	\$																
Amount to be: refunded	\$																					
charged	\$																					
<input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Credit Card Payment form attached. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 501-619 A duplicate copy of this sheet is enclosed.																						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																						
SEND ALL CORRESPONDENCE TO:																						
LICATA, Jane Massey; TYRRELL, Kathleen A. Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 US		 Jane Massey Licata NAME 32,257 REGISTRATION NUMBER 20 November 2000 DATE																				

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (e)) - SMALL BUSINESS CONCERN**

Docket No.
DEX-0113

Serial No.
Not Yet Assigned

Filing Date
Herewith

Patent No.

Issue Date

Applicant/ **YANG, Fei et al.**

Patentee:

Invention: **A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING LUNG CANCER**

I hereby declare that I am:

- the owner of the small business concern identified below:
- an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: diaDexus, Inc.

ADDRESS OF CONCERN: 3303 Octavius Drive, Santa Clara, California 95054

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 37 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:

- the specification filed herewith with title as listed above.
- the application identified above.
- the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- no such person, concern or organization exists.
- each such person, concern or organization is listed below.

FULL NAME _____
ADDRESS _____

Individual Small Business Concern Nonprofit Organization

FULL NAME _____
ADDRESS _____

Individual Small Business Concern Nonprofit Organization

FULL NAME _____
ADDRESS _____

Individual Small Business Concern Nonprofit Organization

FULL NAME _____
ADDRESS _____

Individual Small Business Concern Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Mohan Iyer

TITLE OF PERSON SIGNING

OTHER THAN OWNER: Vice President, Business Development

ADDRESS OF PERSON SIGNING: diaDexus, Inc.

3303 Octavius Drive

Santa Clara, California 95054

SIGNATURE:

Mohan S. Iyer

DATE:

11/2/00

09/700770

PCT/US99/10344

WO 99/60160

- 1 -

**A NOVEL METHOD OF DIAGNOSING,
MONITORING, AND STAGING LUNG CANCER**

FIELD OF THE INVENTION

This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging, and prognosticating cancers, particularly lung cancer.

BACKGROUND OF THE INVENTION

Primary lung cancer is divided into three main types including small cell lung cancer, non-small cell lung cancer, and mesothelioma. Small cell lung cancer is also called "Oat Cell" lung cancer because the cancer cells are a distinctive oat shape. There are three types of non-small cell lung cancer which are grouped together based upon similar behavior patterns and response to treatment which is different from small cell lung cancer. The three types of non-small cell lung cancer are squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Squamous cell cancer is the most common type of lung cancer. It develops from the cells that line the airways. Adenocarcinoma also develops from the cells that line the airways, but it develops from a particular type of cell that produces mucus (phlegm). In large cell lung cancer, the cells appear large and rounded when viewed under a microscope. Mesothelioma is a rare type of cancer which affects the covering of the lung, the pleura. It is often caused by exposure to asbestos.

Secondary lung cancer is cancer that has started somewhere else in the body (for example, the breast or bowel) and spread to the lungs. The choice of treatment depends on where the cancer began. For example, cancer that has spread from the breast should respond to breast cancer treatments and cancer that has spread from the bowel should respond to bowel

- 2 -

cancer treatments. The stage of a cancer provides information regarding how far a cancer has spread. Staging is important because treatment of the cancer is often decided based upon its stage. Staging is different for non-small cell versus small cell cancers of the lung.

Non-small cell cancer is divided into four stages. Stage I is very localized cancer with no cancer in the lymph nodes. In stage II, cancer has spread to the lymph nodes at the top of the affected lung. In stage III, cancer has spread near to where the cancer started. This can be to the chest wall, the covering of the lung (pleura), the middle of the chest (mediastinum) or other lymph nodes. Stage IV cancer has spread to another part of the body.

Small cell lung cancers are divided into two groups. This is because small cell lung cancer often spreads quite early. Even if spreading of the cancer is not visible on scans, it is likely that some cancer cells will have broken away and traveled through the bloodstream or lymph system. Accordingly, it is often preferred to treat small cell lung cancers as if they have spread, whether or not any secondary cancer is seen.

The two stages of small cell lung cancers are limited disease, that is cancer that can only be seen in one lung and in nearby lymph nodes, and extensive disease, that is cancer that has spread outside the lung to the chest or to other parts of the body. Because surgery is not usually used to treat small cell cancer, except in very early cases, the staging is not as important as it is with some other types of cancer. Chemotherapy with or without radiotherapy is usually preferred for treatment of small cell lung cancers. Initial scans and tests are used for comparison with later scans and test to see how well a patient is responding to treatment.

Procedures used for detecting, diagnosing, monitoring, staging and prognosticating lung cancer are of critical importance to the outcome of the patient. For example,

- 3 -

patients diagnosed with early lung cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized lung cancer. New diagnostic methods which are more sensitive and specific for detecting early lung cancer are clearly needed.

Lung cancer patients are also closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. There is clearly a need for a lung cancer marker which is more sensitive and specific in detecting lung cancer recurrence.

Another important step in managing lung cancer is determination of the stage of the disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of lung cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of lung cancer would be improved by detecting new markers in cells, tissues or bodily fluids which could differentiate between different stages of invasion.

In the present invention, methods are provided for detecting, diagnosing, monitoring, staging and prognosticating lung cancer via six (6) Lung Specific Genes (LSGs). The six LSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5 or 6. In the alternative, what is meant by the six LSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5 or 6 or

- 4 -

levels of the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5 or 6.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of lung cancer in a patient which comprises measuring levels of LSG in a sample of cells, tissue or bodily fluid from the patient and comparing the measured levels of LSG with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in the measured LSG levels in the patient versus levels of LSG in the control is associated with lung cancer.

Another object of the present invention is to provide a method of diagnosing metastatic lung cancer in a patient which comprises measuring LSG levels in a sample of cells, tissue, or bodily fluid from the patient and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured LSG levels in the patient versus levels of LSG in the control is associated with a cancer which has metastasized.

Another object of the present invention is to provide a method of staging lung cancer in a patient which comprises identifying a patient having lung cancer, measuring levels of

- 5 -

LSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissue or bodily fluid type of a control. An increase in measured LSG levels in the patient versus LSG levels in the control can be associated with a cancer which is progressing while a decrease or equivalent level of LSG measured in the patient versus the control can be associated with a cancer which is regressing or in remission.

Another object of the present invention is to provide a method of monitoring lung cancer in a patient for the onset of metastasis. The method comprises identifying a patient having lung cancer that is not known to have metastasized, periodically measuring levels of LSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured LSG levels versus control LSG levels is associated with a cancer which has metastasized.

Yet another object of the present invention is to provide a method of monitoring the change in stage of lung cancer in a patient which comprises identifying a patient having lung cancer, periodically measuring levels of LSG in a sample of cells, tissue, or bodily fluid obtained from the patient, and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a control wherein an increase in measured LSG levels versus the control LSG levels is associated with a cancer which is progressing and a decrease in the measured LSG levels versus the control LSG levels is associated with a cancer which is regressing or in remission.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be

BIOLOGICAL MATERIAL

- 6 -

understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, and prognosticating cancers by comparing levels of LSG with those of LSG in a normal human control. What is meant by "levels of LSG" as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, or 6. In the alternative, what is meant by "levels of LSG" as used herein, means levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, or 6 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, or 6. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of LSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including lung cancer. Any of the six LSGs may be measured alone in the methods of the invention, or all together or any combination of the six.

By "control" it is meant a human patient without cancer and/or non cancerous samples from the patient, also referred to herein as a normal human control; in the methods for diagnosing or monitoring for metastasis, control may also

- 7 -

include samples from a human patient that is determined by reliable methods to have lung cancer which has not metastasized.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as LSG. Other cancer markers, in addition to LSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

Diagnostic Assays

The present invention provides methods for diagnosing the presence of lung cancer by analyzing for changes in levels of LSG in cells, tissues or bodily fluids compared with levels of LSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of LSG in the patient versus the normal human control is associated with the presence of lung cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic lung cancer in a patient having lung cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having lung cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of lung cancer, patients are typically diagnosed with lung cancer following traditional detection methods.

- 8 -

In the present invention, determining the presence of LSG level in cells, tissues, or bodily fluid, is particularly useful for discriminating between lung cancer which has not metastasized and lung cancer which has metastasized. Existing techniques have difficulty discriminating between lung cancer which has metastasized and lung cancer which has not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues, or bodily fluid is LSG, and are compared with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is just LSG in serum, this level is preferably compared with the level of LSG in serum of a normal human patient. An increase in the LSG in the patient versus the normal human control is associated with lung cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

Staging

The invention also provides a method of staging lung cancer in a human patient.

The method comprises identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG. Then, the method compares LSG levels in such cells, tissues, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is

- 9 -

associated with a cancer which is progressing and a decrease in the levels of LSG is associated with a cancer which is regressing or in remission.

Monitoring

Further provided is a method of monitoring lung cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this inventions is a method of monitoring the change in stage of lung cancer in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of LSG is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

Assay Techniques

Assay techniques that can be used to determine levels of gene expression, such as LSG of the present invention, in

- 10 -

a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses and ELISA assays. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to LSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to LSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to LSG is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time LSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to LSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to LSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to LSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of LSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

- 11 -

A competition assay may be employed wherein antibodies specific to LSG attached to a solid support and labeled LSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of LSG in the sample.

Nucleic acid methods may be used to detect LSG mRNA as a marker for lung cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the LSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the LSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling

- 12 -

of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

EXAMPLES

The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

Example 1: LSGs

Searches were carried out and LSGs identified using the following Search Tools as part of the LIFESEQ® database available from Incyte Pharmaceuticals, Palo Alto, CA:

1. Library Comparison (compares one library to one other library) allows the identification of clones expressed in tumor and absent or expressed at a lower level in normal tissue.

2. Subsetting is similar to library comparison but allows the identification of clones expressed in a pool of

- 13 -

libraries and absent or expressed at a lower level in a second pool of libraries.

3. Transcript Imaging lists all of the clones in a single library or a pool of libraries based on abundance. Individual clones can then be examined using Electronic Northerns to determine the tissue sources of their component ESTs.

4. Protein Function: Incyte has identified subsets of ESTs with a potential protein function based on homologies to known proteins. Some examples in this database include Transcription Factors and Proteases. Some lead were identified by searching in this database for clones whose component EST's showed disease specificity.

Electronic subtractions, transcript imaging and protein function searches were used to identify clones, whose component EST's were exclusively or more frequently found in libraries from specific tumors. Individual candidate clones were examined in detail by checking where each EST originated.

TABLE 1: LSGs

SEQ ID NO	Clone ID	Gene ID	
1	126758	29997	Library Comparisons
2	2798946	26723	Library Comparisons
3	3107312	242842	Transcript Imaging
4	1472038	51968	Transcript Imaging
5	126263	221807	Transcript Imaging
6	586271	242745	Transcript Imaging

The following example was carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A

- 14 -

LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene was evaluated for every example in normal and cancer tissue. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

PCT/US99/10344

Comparative Examples

For comparative examples similar mRNA expression analysis for genes coding for the diagnostic markers PSA (Prostate Specific Antigen) and PLA2 (Phospholipase A2) was performed. PSA is the only cancer screening marker available in clinical laboratories. When the panel of normal pooled tissues was analyzed, PSA was expressed at very high levels in prostate, with a very low expression in breast and testis. After we analyzed more than 55 matching samples from 14 different tissues, the data corroborated the tissue specificity seen with normal tissue samples. We compared PSA expression in cancer and normal adjacent tissue for 12 matching samples of prostate tissue. The relative levels of PSA were higher in 10 cancer samples (83%). Clinical data recently obtained support the utilization of PLA2 as a staging marker for late stages of prostate cancer. Our mRNA expression data showed overexpression of the mRNA in 8 out of the 12 prostate matching samples analyzed (66%). The tissue specificity for PLA2 was not as good as the one described for PSA. In addition to prostate, also small intestine, liver, and pancreas showed high levels of mRNA expression for PLA2.

**Measurement of SEQ ID NO:1; Clone ID 126758; Gene ID 29997
(Lng101)**

The absolute numbers as depicted in Table 2 are relative levels of expression of LSG Lng101 (SEQ ID NO:1) in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

- 16 -

Table 2: Relative levels of Lng101 Expression in Pooled Samples

Tissue	NORMAL
Brain	0
Heart	1.55
Kidney	0
Liver	0
Lung	72716
Mammary Gland	2
Prostate	0
Small Intestine	0
Spleen	0
Testis	1
Thymus	0
Uterus	0

The relative levels of expression in Table 2 show that mRNA expression of the LSG Lng101 (SEQ ID NO:1) is very high (72716) in lung compared with all the other normal tissues analyzed. Testis, the calibrator, with a relative expression level of 1, heart (1.55), and mammary gland (2) are the only tissues expressing the mRNA for Lng101. These results demonstrated that Lng101 mRNA expression is highly specific for lung.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of Lng101 in 44 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

- 17 -

Table 3: Relative Levels of Lng101 Expression in Individual Samples

Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
Lng AC82	Adenocarcinoma	Lung 1	17199	92042
Lng 60XL	Adenocarcinoma	Lung 2	4603	49971
Lng AC66	Adenocarcinoma	Lung 3	7358	116907
Lng AC69	Adenocarcinoma	Lung 4	82953	47644
Lng AC11	Adenocarcinoma	Lung 5	37771	496008
Lng AC39	Adenocarcinoma	Lung 6	2487	15771
Lng AC32	Adenocarcinoma	Lung 7	12634	204254
Lng SQ9X	Squamous cell carcinoma	Lung 8	90774	14462
Lng SQ32	Squamous cell carcinoma	Lung 9	6677	677567
Lng SQ80	Squamous cell carcinoma	Lung 10	50711	47151
Lng SQ16	Squamous cell carcinoma	Lung 11	396	41333
Lng SQ79	Squamous cell carcinoma	Lung 12	10261	354395
Lng 47XQ	Squamous cell carcinoma	Lung 13	2513	5293
Lng SQ44	Squamous cell carcinoma	Lung 14	69033	72
Lng 90X	Squamous cell carcinoma	Lung 15	678	14715
Lng LC71	Large cell carcinoma	Lung 16	155332	44762
Lng LC109	Large cell carcinoma	Lung 17	10191	322737
Lng 75XC	Metastatic from bone cancer	Lung 18	222033	165291
Lng MT67	Metastatic from renal cell cancer	Lung 19	189	35982

- 18 -

Lng MT71	Metastatic from melanoma	Lung 20	122	4270
Bld 32XK		Bladder 1	0	0
Bld 46XK		Bladder 2	0	0
Cln AS45		Colon 1	0	0
Cln C9XR		Colon 2	0	0
Cvx KS52		Cervix 1	0	0
Cvx NK23		Cervix 2	0	0
End 28XA		Endometrium 1	0	0
End 12XA		Endometrium 2	0	0
Kid 106XD		Kidney 1	0	0
Kid 107XD		Kidney 2	0	0
Liv 94XA		Liver 1	0	0
Liv 15XA		Liver 2	0	0
Mam 82XI		Mammary 1	0	0
Mam A06X		Mammary 2	0	0
Pan 71XL		Pancreas 1	0	0
Pan 77X		Pancreas 2	0	0
Pro 20XB		Prostate 1	0	0
Pro 12B		Prostate 2	0	0
SmI 21XA		Sm. Int. 1	0	0
SmI H89		Sm. Int. 2	0	0
Sto AC44		Stomach	13	0
Tst 39X		Testis	4315	0
Utr 135XO		Uterus 1	0	0
Utr 141XO		Uterus 2	0	0

0= Negative

- 19 -

In the analysis of matching samples, the higher levels of expression were in lung, showing a high degree of tissue specificity for this tissue. These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 2).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of LSG Lng101 in 6 lung cancer tissues compared with their respective normal adjacent (lung samples #4, 8, 10, 14, 16, and 18). There was overexpression in the cancer tissue for 30% of the lung matching samples tested (total of 20 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 30% of the lung matching samples tested are demonstrative of LSG Lng101 (SEQ ID NO:1) being a diagnostic marker for lung cancer. The amino acid sequence encoded by Lng101 (SEQ ID NO:1) is depicted in SEQ ID NO: 7.

**Measurement of SEQ ID NO:3; Clone ID 3107312; Gene ID 242842
(Lng105)**

The absolute numbers depicted in Table 4 are relative levels of expression of LSG Lng105 (SEQ ID NO:3) in 12 normal different tissues. All the values are compared to normal kidney (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

- 20 -

Table 4: Relative levels of Lng105 Expression in Pooled Samples

Tissue	NORMAL
Brain	1
Heart	1.11
Kidney	558
Liver	0
Lung	9248
Mammary Gland	6
Muscle	0
Prostate	0
Small Intestine	87
Testis	50
Thymus	6
Uterus	23

The relative levels of expression in Table 4 show that mRNA expression of LSG Lng105 (SEQ ID NO:3) is more than 16 fold higher in the pool of normal lung (9248) compared with the next higher expressor (558 for kidney). All the other pooled tissues samples analyzed showed a very low level of expression for Lng105 (SEQ ID NO:3). These results demonstrate that mRNA expression of LSG Lng105 (SEQ ID NO:3) is highly specific for lung.

The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 5.

The absolute numbers depicted in Table 5 are relative levels of expression of Lng105 (SEQ ID NO:3) in 61 pairs of matching samples. All the values are compared to normal small intestine (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

- 21 -

Table 5: Relative Levels of Lng105 Expression in Individual Samples

Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
Lng AC82	Adenocarcinoma	Lung 1	1278	742
Lng C17X	Adenocarcinoma	Lung 2	1272	1948
Lng 60XL	Adenocarcinoma	Lung 3	4345	2188
Lng AC66	Adenocarcinoma	Lung 4	1531	1558
Lng AC69	Adenocarcinoma	Lung 5	7232	913
Lng AC88	Adenocarcinoma	Lung 6	7724	24749
Lng AC11	Adenocarcinoma	Lung 7	690	21545
Lng AC39	Adenocarcinoma	Lung 8	16904	370
Lng AC90	Adenocarcinoma	Lung 9	14614	34
Lng AC32	Adenocarcinoma	Lung 10	8720	5061
Lng SQ9X	Squamous cell carcinoma	Lung 11	3603	659
Lng SQ45	Squamous cell carcinoma	Lung 12	32998	1333
Lng SQ56	Squamous cell carcinoma	Lung 13	829	15077
Lng SQ14	Squamous cell carcinoma	Lung 14	7	6865
Lng SQ32	Squamous cell carcinoma	Lung 15	976	10227
Lng SQ80	Squamous cell carcinoma	Lung 16	2769	3554
Lng SQ16	Squamous cell carcinoma	Lung 17	198	292
Lng SQ79	Squamous cell carcinoma	Lung 18	1128	7777
Lng C20X	Squamous cell carcinoma	Lung 19	4	20
Lng 47XQ	Squamous cell carcinoma	Lung 20	276	117

- 22 -

Lng SQ44	Squamous cell carcinoma	Lung 21	3126	1
Lng BR94	Squamous cell carcinoma	Lung 22	709	6
Lng 90X	Squamous cell carcinoma	Lung 23	258	590
Lng LC71	Large cell carcinoma	Lung 24	155332	44762
Lng LC109	Large cell carcinoma	Lung 25	34280	33112
Lng 75XC	Metastatic from bone cancer	Lung 26	749	902
Lng MT67	Metastatic from renal cell cancer	Lung 27	70	6985
Lng MT71	Metastatic from melanoma	Lung 28	742	15992
Bld 32XK		Bladder 1	1	0
Bld 46XK		Bladder 2	0	0
Cvx KS52		Cervix 1	4	0
Cvx NK23		Cervix 2	1	0
Cln AS45		Colon 1	0	1
Cln C9XR		Colon 2	2	1
Cln CM67		Colon 3	0	0
End 28XA		Endometrium 1	7	4
End 12XA		Endometrium 2	0	0
Kid 106XD		Kidney 1	0	186
Kid 107XD		Kidney 2	82	458
Kid 109XD		Kidney 3	169	438
Kid 10XD		Kidney 4	21	186
Kid 11XD		Kidney 5	586	110
Liv 94XA		Liver 1	1	0

- 23 -

Liv 15XA		Liver 2	1	0
Mam A06X		Mammary 1	1	0
Mam B011X		Mammary 2	13	0
Mam 12X		Mammary 3	0	0
Mam 59X		Mammary 4	0	0
Ovr 103X		Ovary 1	15	2
Pan 71XL		Pancreas 1	1	0
Pan 77X		Pancreas 2	4	0
Pro 20XB		Prostate 1	1	1
Pro 12B		Prostate 2	8	0
Sml 21XA		Sm. Int. 1	4	0
Sml H89		Sm. Int. 2	1	0
Sto AC44		Stomach 1	0	2
Sto AC99		Stomach 2	6	2
Tst 39X		Testis	28	2
Utr 85XU		Uterus 1	3	2
Utr 135XO		Uterus 2	2	0
Utr 141XO		Uterus 3	2	6

0= Negative

In the analysis of matching samples, the higher levels of expression were in lung showing a high degree of tissue specificity for lung tissue. These results confirm the tissue specificity results obtained with normal pooled samples (Table 4).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the

- 24 -

normal adjacent). Table 5 shows overexpression of LSG Lng105 (SEQ ID NO:3) in 13 lung cancer tissues compared with their respective normal adjacent (lung samples #1, 3, 5, 8, 9, 10, 11, 12, 20, 21, 22, 24, and 25). There is overexpression in the cancer tissue for 46% of the colon matching samples tested (total of 28 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in almost half of the lung matching samples tested are demonstrative of Lng105 (SEQ ID NO:3) being a diagnostic marker for lung cancer. The amino acid sequence encoded by Lng105 (SEQ ID NO:3) is depicted as SEQ ID NO:8.

**Measurement of SEQ ID NO:6; Clone ID 586271; Gene ID 242745
(Lng107)**

The absolute numbers depicted in Table 6 are relative levels of expression of LSG Lng107 (SEQ ID NO:6) in 12 normal different tissues. All the values are compared to normal mammary gland (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 6: Relative levels of Lng107 Expression in Pooled Samples

Tissue	NORMAL
Bladder	0
Heart	0
Kidney	0
Liver	0
Lung	23
Mammary Gland	1
Muscle	0
Prostate	0
Small Intestine	0
Testis	0
Thymus	0
Uterus	0

- 25 -

The relative levels of expression in Table 6 show that mRNA expression of LSG Lng107 (SEQ ID NO:6) is 23 fold higher in the pool of normal lung (23) compared to the expression level in the calibrator mammary gland (1). All the other tissues analyzed were negative for Lng107 (SEQ ID NO:6). These results demonstrate that Lng107 mRNA expression is highly specific for lung.

The absolute numbers in Table 6 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 7.

The absolute numbers depicted in Table 7 are relative levels of expression of LSG Lng107 (SEQ ID NO:6) in 57 pairs of matching samples. All the values are compared to normal prostate (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Table 7: Relative Levels of Lng107 Expression in Individual Samples

Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
Lng AC82	Adenocarcinoma	Lung 1	6	2
Lng 60XL	Adenocarcinoma	Lung 2	1	4
Lng AC66	Adenocarcinoma	Lung 3	1	0
Lng AC69	Adenocarcinoma	Lung 4	117	6
Lng AC88	Adenocarcinoma	Lung 5	12	6
Lng AC11	Adenocarcinoma	Lung 6	1	18
Lng AC32	Adenocarcinoma	Lung 7	4	2
Lng AC39	Adenocarcinoma	Lung 8	2	1
Lng AC90	Adenocarcinoma	Lung 9	1	0
Lng SQ9X	Squamous cell	Lung 10	7	0

- 26 -

Lng SQ45	Squamous cell carcinoma	Lung 11	45	1
Lng SQ56	Squamous cell carcinoma	Lung 12	1	23
Lng SQ16	Squamous cell carcinoma	Lung 13	0	0
Lng SQ32	Squamous cell carcinoma	Lung 14	9	5
Lng SQ80	Squamous cell carcinoma	Lung 15	2	0
Lng SQ79	Squamous cell carcinoma	Lung 16	5	11
Lng C20X	Squamous cell carcinoma	Lung 17	0	0
Lng 47XQ	Squamous cell carcinoma	Lung 18	1	0
Lng SQ44	Squamous cell carcinoma	Lung 19	1	0
Lng BR94	Squamous cell carcinoma	Lung 20	1	0
Lng 90X	Squamous cell carcinoma	Lung 21	0	13
Lng LC71	Large cell carcinoma	Lung 22	31	12
Lng LC109	Large cell carcinoma	Lung 23	1	83
Lng 75XC	Metastatic from bone cancer	Lung 24	2	4
Lng MT67	Metastatic from renal cell cancer	Lung 25	0	1
Lng MT71	Metastatic from melanoma	Lung 26	0	24
Bld 32XK		Bladder 1	0	0
Bld 46XK		Bladder 2	0	0
Cln AS45		Colon 1	0	0
Cln C9XR		Colon 2	0	0

- 27 -

Cvx KS52	Cervix 1	0	0
Cvx NK23	Cervix 2	0	0
End 28XA	Endometrium 1	7	0
End 12XA	Endometrium 2	0	0
End 68X	Endometrium 3	3	2
End 8XA	Endometrium 4	0	0
Kid 106XD	Kidney 1	0	0
Kid 107XD	Kidney 2	0	0
Liv 94XA	Liver 1	0	0
Liv 15XA	Liver 2	0	0
Mam A06X	Mammary 1	0	0
Mam B011X	Mammary 2	116	0
Mam 47XP	Mammary 3	0	0
Mam 59X	Mammary 4	1	0
Ovr 103X	Ovary 1	0	0
Pan 71XL	Pancreas 1	0	0
Pan 77X	Pancreas 2	0	0
Pro 20XB	Prostate 1	0	0
Pro 12B	Prostate 2	0	0
Sml 21XA	Sm. Int. 1	0	0
Sml H89	Sm. Int. 2	0	0
Sto AC44	Stomach 1	0	0
Sto MT54	Stomach 2	0	0
Sto TA73	Stomach 3	1	1
Tst 39X	Testis	0	0
Utr 135XO	Uterus 1	0	0
Utr 141XO	Uterus 2	0	0

- 28 -

0= Negative

In the analysis of matching samples, the higher level of expression was in lung, showing a high degree of tissue specificity for this tissue. These results confirm the tissue specificity results obtained with normal pooled samples (Table 6).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 7 shows overexpression of LSG Lng107 (SEQ ID NO:6) in 15 lung cancer tissues compared with their respective normal adjacent (lung samples #1, 3, 4, 5, 7, 8, 9, 10, 11, 14, 15, 18, 19, 20, and 22). There is overexpression in the cancer tissue for 57% of the lung matching samples tested (total of 26 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in more than half of the lung matching samples tested are demonstrative of Lng107 being a diagnostic marker for lung cancer. The amino acid sequence encoded by Lng107 is depicted in SEQ ID NO:9.

- 29 -

What is Claimed is:

1. A method for diagnosing the presence of lung cancer in a patient comprising:
 - (a) measuring levels of LSG in a sample of cells, tissue or bodily fluid obtained from the patient; and
 - (b) comparing the measured levels of LSG with levels of LSG in a sample of cells, tissue or bodily fluid obtained from a control, wherein an increase in measured levels of LSG in the patient versus the LSG levels in the control is associated with the presence of lung cancer.
2. A method of diagnosing metastatic lung cancer in a patient comprising:
 - (a) measuring levels of LSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and
 - (b) comparing the measured levels of LSG with levels of LSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in measured LSG levels in the patient versus the LSG levels in the control is associated with a cancer which has metastasized.
3. A method of staging lung cancer in a patient comprising:
 - (a) identifying a patient suffering from lung cancer;
 - (b) measuring levels of LSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and
 - (c) comparing the measured levels of LSG with levels of LSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in the measured levels of LSG versus the levels of LSG in the control is associated with a cancer which is progressing and a decrease in the measured levels of LSG versus the levels of LSG in the control is associated with a cancer which is regressing or in remission.

- 30 -

4. A method of monitoring lung cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having lung cancer that is not known to have metastasized;

(b) periodically measuring LSG levels in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the periodically measured levels of LSG with levels of LSG in cells, tissue, or bodily fluid obtained from a control, wherein an increase in any one of the periodically measured levels of LSG in the patient versus the levels of LSG in the control is associated with a cancer which has metastasized.

5. A method of monitoring changes in a stage of lung cancer in a patient comprising:

(a) identifying a patient having lung cancer;

(b) periodically measuring levels of LSG in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of LSG with levels of LSG in a sample of the same cells, tissue, or bodily fluid of a control, wherein an increase in any one of the periodically measured levels of LSG versus levels of LSG in the control is associated with a cancer which is progressing in stage and a decrease in any one of the periodically measured levels of LSG versus the levels of LSG in the control is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4, or 5 wherein the LSG comprises SEQ ID NO: 1, 3 or 6.

09/700770

PCT/US99/10344

WO 99/60160

SEQUENCE LISTING

<110> Yang, Fei
Macina, Roberto A.
Sun, Yongming

<120> A Novel Method of Diagnosing, Monitoring and Staging
Lung Cancer

<130> DEX-0036

<140>
<141>

<150> 60/086,212
<151> 1998-05-21

<160> 9

<170> PatentIn Ver. 2.0

<210> 1
<211> 507
<212> DNA
<213> Homo sapiens

<400> 1
ggcaagtgga accactggct tggtgattt tgcttagattt ttctgatttt taaaactcctg 60
aaaaatatcc cagataactg tcatgaagct ggtaactatc ttccctgctgg tgaccatcg 120
cctttgttgt tactctgcta ctgccttcct catcaacaaa gtgccccttc ctgttgacaa 180
gttggcacct ttacacctgg acaacattct tccctttatg gatccattaa agcttctct 240
gaaaactctg ggcatctctg ttgagcacct tgtggggggg ctaaggaagt gtgtaaatga 300
gctgggacca gaggctctg aagctgtgaa gaaactgctg gaggcgctat cacacttgg 360
gtgacatcaa gataaagagc ggaggtggat ggggatggaa gatgtatgctc ctatcctccc 420
tgcctgaaac ctgttctacc aattatagat caaatgcctt aaaatgttagt gaccgtgaa 480
aaggacaaat aaagcaatga atacatt 507

<210> 2
<211> 1680
<212> DNA
<213> Homo sapiens

<400> 2
ggtgtgcagg atataagggtt ggacttccag acccaactgcc cgggagagga grggagcggg 60
ccgaggactc cagcgtgccc aggtctggca tcctgcactt gtcgcctct gacacctggg 120
aagatggccg gcccgtggac ctccaccctt ctctgtgggt tgctggcagc caccttgatc 180
caagccaccc tcagtcacac tgcaaggatc atccctggcc caaaagtcat caaagaaaag 240
ctgacacacagg agctgaagga ccacaacgcc accagcatcc tgcaaggatc gcccgtgctc 300

agtgccatgc gggaaaagcc agccggagga tccctgtgct gggcagcctg gtgaacacccg 360
 tcctgaagca catcatctgg ctgaaggta tcacagctaa catcctccag ctgcaggtga 420
 agccctcgcc caatgaccag gagctgttag tcaagatccc cctggacatg gtggctggat 480
 tcaaacacgcc cctggtaaq accatgtgg agttccacat gacgactgag gcccaaggcca 540
 ccatccqcat ggacaccagt gcaagtggcc ccacccgcct gtcctcagt gactgtgcca 600
 ccagccatgg gaggctgcgc atccaactgc tgcatataagct ctcccttcctg gtgaacgcct 660
 tagctaagca ggtcatgaac ctccctgtgc catccctgccc caatcttagt aaaaaccagc 720
 tgtgtccccgt gatcgaggct tccttcaatg qcatgtatgc agacccctcg cagctggta 780
 aggtgccccat ttccctcagc attgaccgtc tggagtttga ctttctgtat ctcgcctca 840
 agggtgacac cattcagtc tacctgggg ccaagttgtt ggactcacag ggaaagggtga 900
 ccaagtggtt caataactct gcagcttccc tgacaatgccc caccctggac aacatcccg 960
 tcagcctcat cgtgagtcag gacgtggta aagctgcagt ggctgctgtg ctctctccag 1020
 aagaattcat ggtccctgttgc gactctgtgc ttccctgagag tgcccatcggt ctgaagtc 1080
 gcatcgggct gatcaatgaa aaggctgcag ataagctggg atctaccctg atcgtgaaga 1140
 tccttaactca ggacactccc gagttttta tagaccaagg ccatgccaag gtggcccaac 1200
 tgatctgtgc ggaagtgttt ccctccagtg aagccctccg ccctttgttc accctggca 1260
 tcgaagccag ctccggaaatc cagtttaca ccaaaggta ccaacttata ctcaacttga 1320
 ataacatcag ctctgtatgg atccagctga tgaactctgg gattggctgg ttccaacctg 1380
 atgttctgaa aaacatcato actgagatca tccactccat cctgctgccc aaccagaatg 1440
 gcaaattaag atctggggtc ccagtgtcat tggtaaggc cttgggattc gaggcagctg 1500
 agtcctcaact gaccaaggat gcccctgtgc ttactccagc ctccctgtgg aaaccaggct 1560
 ctccctgtctc ccagtgaaga ctggatggc agccatcagg gaaggctggg tcccagctgg 1620
 gagtatgggt gtgagctcta tagaccatcc ctctctgca tcaataaaaca ctgcctgtg 1680

<210> 3
 <211> 2060
 <212> DNA
 <213> Homo sapiens

<400> 3
 cttgagagct ctcaaataact tggcatgga tgaagccgac cgaataactga atatggattt 60
 tgagacagag gttgacaagc ctccggatcg gaaaacattc ctcttctctg ccaccatgac 120
 caagaagggtt caaaaacttc aycgagcgc tctgaagaat cctgtgaaat gtcccgittc 180
 ctctaaatac cagacagttg aaaaattaca gcaatattat atttttattt cctctaaatt 240
 caaggatacc tacctgggtt atattctaaa tgaattggct ggaaactcct ttatgtatatt 300
 ctgcggcacc tgaataata cccagagaac agctttgtca ctgcgaaatc ttggcttcac 360
 tgccatcccc ctccatggac aaatgatcg gagaaggcgc cttagatccc ttaataagtt 420
 taaggccaag gcccgttcca ttcttcttagc aactgacgtt gccagccgag gtttggacat 480
 acctcatgtt gatgtgggtt tcaactttga catttctacc catttcaagg attacatcca 540
 tcgagtaggt cgaacagctt gaggctggcg ctccggaaag gctattactt ttgtcacaca 600
 gtatgtatgtt gaaactcttcc aycgcataaga acacttaatt gggaaagaaac taccagggtt 660
 tccaaacacag gatgtatgtt gacgaaacgc gtccccagcg atgtctccac 720
 caccgtgtgtt gcaacccctt ctgtgtgtc tgcctctgtt gatgtggag cttccgggg 780
 ccacactgtt ccgcattccct ctccatcgag tccaaacctgg acgcaggacc ctgaacccat 840
 tgaggggatgtt gagaaggatcca gcaagggtggg ggcccccattcc cctggggac 900
 agcccatctt cgtacacttcc tcaactaca gggatgtgca gtatgttggg gaaattgggc 960
 tggaaacgccc tccacaaaaac ttcaactgttgc ctttgcacac tggctctcc aatctctggg 1020
 tcccgccatgggtt gatgtccatgtt gtcctgttgc gttacaccac cgatttgatc 1080

ccaaaggcctc tagtccttc caggccaatg ggaccaagtt tgccattcaa tatggaaactg 1140
 ggcgggtaga tggaaatcctg agcgaggaca agctgactat tggtggaaatc aagggtgcata 1200
 cagtgatatt cggggaggct ctctgggagc ccagcctggc cttcgctttt gcccattttg 1260
 atggatattt gggcctcggt ttccccatc tgcgtgtgga aggagttcg ccccccgtatgg 1320
 atgtactggt ggagcagggg ctattggata agcctgtctt ctccctttac ctcaacaggg 1380
 accctgaaga gcctgatgga ggagagctgg tcctgggggg ctccggaccgc gcacactaca 1440
 tcccacccct cacctcggt ccagtcacgg tccctgccta ctggcagatc cacatggagc 1500
 gtgtgaaggt gggcccagggg ctgactctt gtgccaagggg ctgtgtgtcc atccctggata 1560
 cgggcacgta cctcatcaca ggacccactg aggagatccg ggcctgtcat gcageccattg 1620
 ggggaatcccc ctgtggct ggggagata tcatcctgtg ctccggaaatc ccaaagctcc 1680
 cccgagtcctc cttcccttctt ggggggggtct ggtttaacct cacggcccat gattacgtca 1740
 tccagactac tcgaaatggc gtccgcctct gcttgccgg ttccaggcc ctggatgtcc 1800
 ctccgcctgc aggcccttc tggatcctcg gtgacgtctt ctgggggacg tatgtggccg 1860
 tcttcgaccc cggggacatg aagagcageg cccgggtggg ctggcgcgc gtcgcactc 1920
 ggggagcggg cctcgatgg ggagagactg cgcaggcgcga gttccccggg tgacgcccaa 1980
 gtgaagcgcga tgccgagcgg gtgtcgccg aggtcctgtc acccagtaaa aatccactat 2040
 ttccattgaa aaaaaaaaaaa 2060

<210> 4

<211> 315

<212> DNA

<213> Homo sapiens

<400> 4

taaacactga ctcagatattt aagaataaac ttttgagaaa tagaacaaat gaaatcagtt 60
 tctccaccac ttaagtatat ctcttagaga tctacagcct ccctttaggg gacataaaaa 120
 gtcagttgtg ttgcctttgt tgagtcacac cttatattca agtaggtatg actacaaatt 180
 ttgaaaatag attgtcacac aataaaactgg agtttatgga aacatcagta gaaggaaata 240
 caacattcca tcccttaca gagatcattt acttgcaact caggataatt tgtcatgtgt 300
 attatctact tatgc 315

<210> 5

<211> 895

<212> DNA

<213> Homo sapiens

<400> 5

ctaatctgtt acgtaaacagc aagacagcgt cacctcacct gttctcgccc tcaaattggg 60
 acgctggctt gggactaaag catagaccac caggctgagt atcctgaccc gagtcatccc 120
 cagggatcag gagcctccag cagggAACCT tccattatat tcttcaagca acttacagct 180
 gcaccgacag ttgcgtgaa agttctaaatc tttccctcc tccctgtgtc gccactaatg 240
 ctgatgtcca tggctcttag cagcctgaat ccagggtcg ccagaggcca cagggaccga 300
 ggcctaggctt cttaggatg gctccaggaa ggcggccaag aatgtgagtg caaagattgg 360
 ttcttgagag ccccgagaag aaaattcatg acagtgtctg ggctgccaagaa gaagcagtgc 420
 ccctgtgatc atttcaaggg caatgtgaag aaaacaagac accaaaggca ccacagaaag 480
 ccaaacaagc attccagagc ctgccagcaa tttctcaaaatc aatgtcagct aagaagcttt 540
 gctctgcctt tgttaggatgt ctgagcgcctt actcttccaa ttaaacatcc tcagccaaga 600
 agacagttag cacacactt cttctccac ctcactctcc cactgtaccc 660

acccctaaat cattccagtq ctctaaaaa gcatgtttt caagatcatt ttgtttgtg 720
 ctctctctag tgcgttc tctcgtaqt cttagcctgt gccctccct tacccagget 780
 taggctaat tacctgaaag attccagaa actgttagctt cctagctgt gtcatttaac 840
 cttaaatgca atcaggaaag tagcaaacag aagtcaataa atattttaa atgtc 895

<210> 6

<211> 543

<212> DNA

<213> Homo sapiens

<400> 6

ccggcgctgg agggcggagg accgggtata agaaggctcg tggccttgcg cgggcagccg 60
 caggttcccc gcgcgcggc agccccccgcg ccatgaagct cgccgcgcctc ctggggctct 120
 gcgtggccct gtccgtcagc tccgtgtcg ctttcttagt gggtcgccg aagcctgtgg 180
 cccagcctgt cgctgcgtg gagtcggcgg cggaggccgg ggcggggacc ctggccaacc 240
 ccctcggcac cctcaacccg ctgaagctcc tgctgagcag cctggcatac cccgtaaacc 300
 acctcataga gggctcccag aagtgtgtgg ctgagctggg tcccccaggcc gtggggggccg 360
 tgaaggccct gaaggccctg ctggggcccc tgacagtgtt tggctgagcc gagactggag 420
 catctacacc tgaggacaag acgctgccc cccgcgaggg ctgaaaaccc cgcgcgggg 480
 aggaccgtcc atccccctcc cccggccct ctcaataaaac gtggtaaga gcaaaaaaaa 540
 aaa 543

<210> 7

<211> 93

<212> PRT

<213> Homo sapiens

<400> 7

Met	Lys	Leu	Val	Thr	Ile	Phe	Leu	Leu	Val	Thr	Ile	Ser	Leu	Cys	Ser
1															

5

10

15

Tyr	Ser	Ala	Thr	Ala	Phe	Leu	Ile	Asn	Lys	Val	Pro	Leu	Pro	Val	Asp

20

25

30

Lys	Leu	Ala	Pro	Leu	Pro	Leu	Asp	Asn	Ile	Leu	Pro	Phe	Met	Asp	Pro

35

40

45

Leu	Lys	Leu	Leu	Lys	Thr	Leu	Gly	Ile	Ser	Val	Glu	His	Leu	Val

50

55

60

Glu	Gly	Leu	Arg	Lys	Cys	Val	Asn	Glu	Leu	Gly	Pro	Glu	Ala	Ser	Glu

65

70

75

80

Ala	Val	Lys	Leu	Leu	Glu	Ala	Leu	Ser	His	Leu	Val

85

90

<210> 8

<211> 420

<212> PRT

<213> Homo sapiens

<400> 8

Met	Ser	Pro	Pro	Pro	Leu	Leu	Gln	Pro	Leu	Leu	Leu	Leu	Leu	Pro	Leu
1					5			10						15	

Leu	Asn	Val	Glu	Pro	Ser	Gly	Ala	Thr	Leu	Ile	Arg	Ile	Pro	Leu	His
								20			25			30	

Arg	Val	Gln	Pro	Gly	Arg	Arg	Thr	Leu	Asn	Leu	Leu	Arg	Gly	Trp	Arg
					35			40				45			

Glu	Pro	Ala	Glu	Leu	Pro	Lys	Leu	Gly	Ala	Pro	Ser	Pro	Gly	Asp	Lys
						50		55			60				

Pro	Ile	Phe	Val	Pro	Leu	Ser	Asn	Tyr	Arg	Asp	Val	Gln	Tyr	Phe	Gly
	65				70			75				80			

Glu	Ile	Gly	Leu	Gly	Thr	Pro	Pro	Gln	Asn	Phe	Thr	Val	Ala	Phe	Asp
					85			90			95				

Thr	Gly	Ser	Ser	Asn	Leu	Trp	Val	Pro	Ser	Arg	Arg	Cys	His	Phe	Phe
					100			105			110				

Ser	Val	Pro	Cys	Trp	Leu	His	His	Arg	Phe	Asp	Pro	Lys	Ala	Ser	Ser
					115			120			125				

Ser	Phe	Gln	Ala	Asn	Gly	Thr	Lys	Phe	Ala	Ile	Gln	Tyr	Gly	Thr	Gly
					130		135			140					

Arg	Val	Asp	Gly	Ile	Leu	Ser	Glu	Asp	Lys	Leu	Thr	Ile	Gly	Ile	
	145				150			155			160				

Lys	Gly	Ala	Ser	Val	Ile	Phe	Gly	Glu	Ala	Leu	Trp	Glu	Pro	Ser	Leu
					165			170			175				

Val	Phe	Ala	Phe	Ala	His	Phe	Asp	Gly	Ile	Leu	Gly	Leu	Gly	Phe	Pro
					180			185			190				

Ile	Leu	Ser	Val	Glu	Gly	Val	Arg	Pro	Pro	Met	Asp	Val	Leu	Val	Glu
						195		200			205				

Gln	Gly	Leu	Leu	Asp	Lys	Pro	Val	Phe	Ser	Phe	Tyr	Leu	Asn	Arg	Asp
					210			215			220				

Pro	Glu	Glu	Pro	Asp	Gly	Gly	Glu	Leu	Val	Leu	Gly	Gly	Ser	Asp	Pro
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

225	230	235	240
Ala His Tyr Ile Pro Pro Leu Thr Phe Val Pro Val Thr Val Pro Ala			
245	250	255	
Tyr Trp Gln Ile His Met Glu Arg Val Lys Val Gly Pro Gly Leu Thr			
260	265	270	
Leu Cys Ala Lys Gly Cys Ala Ala Ile Leu Asp Thr Gly Thr Ser Leu			
275	280	285	
Ile Thr Gly Pro Thr Glu Glu Ile Arg Ala Leu His Ala Ala Ile Gly			
290	295	300	
Gly Ile Pro Leu Leu Ala Gly Glu Tyr Ile Ile Leu Cys Ser Glu Ile			
305	310	315	320
Pro Lys Leu Pro Ala Val Ser Phe Leu Leu Gly Gly Val Trp Phe Asn			
325	330	335	
Leu Thr Ala His Asp Tyr Val Ile Gln Thr Thr Arg Asn Gly Val Arg			
340	345	350	
Leu Cys Leu Ser Gly Phe Gln Ala Leu Asp Val Pro Pro Pro Ala Gly			
355	360	365	
Pro Phe Trp Ile Leu Gly Asp Val Phe Leu Gly Thr Tyr Val Ala Val			
370	375	380	
Phe Asp Arg Gly Asp Met Lys Ser Ser Ala Arg Val Gly Leu Ala Arg			
385	390	395	400
Ala Arg Thr Arg Gly Ala Asp Leu Gly Trp Gly Glu Thr Ala Gln Ala			
405	410	415	
Gln Phe Pro Gly			
420			

<210> 9
<211> 104
<212> PRT
<213> Homo sapiens

<400> 9
Met Lys Leu Ala Ala Leu Leu Gly Leu Cys Val Ala Leu Ser Cys Ser
1 5 10 15

Ser Ala Ala Ala Phe Leu Val Gly Ser Ala Lys Pro Val Ala Gln Pro
20 25 30

Val Ala Ala Leu Glu Ser Ala Ala Glu Ala Gly Ala Gly Thr Leu Ala
35 40 45

Asn Pro Leu Gly Thr Leu Asn Pro Leu Lys Leu Leu Ser Ser Leu
50 55 60

Gly Ile Pro Val Asn His Leu Ile Glu Gly Ser Gln Lys Cys Val Ala
65 70 75 80

Glu Leu Gly Pro Gln Ala Val Gly Ala Val Lys Ala Leu Lys Ala Leu
85 90 95

Leu Gly Ala Leu Thr Val Phe Gly
100

Docket No.

DEX-0113

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING LUNG CANCER

the specification of which

(check one)

is attached hereto.

was filed on 12 May 1999 as United States Application No. or PCT International Application Number PCT/US99/10344

and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/086,212

May 21, 1998

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*list name and registration number*)



26259

PATENT TRADEMARK OFFICE

Send Correspondence to:

Direct Telephone Calls to: (*name and telephone number*)
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <u>Fei Yang</u>	
Sole or first inventor's signature 	Date 12/30/2000
Residence <u>San Diego, California</u>	
Citizenship <u>China</u>	
Post Office Address <u>12227 Branicole Lane</u>	
<u>San Diego, California</u>	

Full name of second inventor, if any <u>Roberto A. Macina</u>	
Second inventor's signature 	Date
Residence <u>San Jose, California</u>	
Citizenship <u>US</u>	
Post Office Address <u>4118 Crescendo Avenue</u>	
<u>San Jose, California</u>	

Full name of third inventor, if any <u>Yongming Sun</u>	
Third inventor's signature <i>CA</i>	Date
Residence <u>San Jose, California</u>	
Citizenship <u>US</u>	
Post Office Address 869 S. Winchester Boulevard, Apt. 260	
San Jose, California	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Docket No.

DEX-0113

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING LUNG CANCER

the specification of which

(check one)

is attached hereto.

was filed on 12 May 1999 as United States Application No. or PCT International Application Number PCT/US99/10344

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/086,212

May 21, 1998

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*list name and registration number*)



26259


PATENT TRADEMARK OFFICE

Send Correspondence to:

Direct Telephone Calls to: (*name and telephone number*)
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor Fei Yang	Date
Sole or first inventor's signature	
Residence San Diego, California	
Citizenship US	
Post Office Address 18375 Caminito Cantilena, Apt. 204	
San Diego, California	

Full name of second inventor, if any Roberto A. Macina	Date
Second inventor's signature <i>[Signature]</i>	<i>11/7/00</i>
Residence San Jose, California	
Citizenship US	
Post Office Address 4118 Crescendo Avenue	
San Jose, California	

Full name of third inventor, if any Yongming Sun	Third inventor's signature 	Date 11-6-2000
Residence San Jose, California		
Citizenship US		
Post Office Address 869 S. Winchester Boulevard, Apt. 260		
San Jose, California		

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	